2026-10-12T22:48:16Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33734242 2026-09-14T11:46:57Z category_696 portal_316 item_type_3 month_year_09_2026

Supplementary file 1_CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness.xls Runqiu Chen (18240979) Xiaoyu Pang (16145279) Fanglin Li (6112280) Shanna Wu (3384905) Yiting Wang (169115) Xinhang Zheng (6630032) Yaqi Zhao (397321) Fengru Qiu (24880549) Liying Chen (4223026) Fengyu Du (9131929) Chen Chen (6544) Rong Zhang (44942) Zhiying Li (703571) Yiru Long (22177924) Likun Gong (172599) Meiqing Feng (447657) Genetic Immunology adeno-associated virus chemotherapy CMTM6 immunotherapy PD-L1 <p>Chemotherapy is one of the important clinical treatments for malignant tumors, but primary or acquired chemotherapy resistance significantly limits patient benefits. Programmed death ligand 1 (PD-L1) has been reported to be regulated by chemotherapy and to contribute to chemotherapy resistance. However, as a novel regulatory molecule of PD-L1, the relationship between CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) and chemotherapy resistance remains understudied. Here, we found that tumor CMTM6 and PD-L1 were upregulated by chemotherapy in clinical cancer patients, in vitro human or mouse tumor models, and in vivo mouse tumor models. PI3K-mTOR was the potential mechanism underlying this effect. CMTM6 deficiency could still reduce chemotherapy-induced tumor PD-L1 expression. And CMTM6 could promote tumor cell resistance to chemotherapy-induced apoptosis and growth arrest, which may be associated with p53. In vivo, both tumor and host CMTM6 and PD-L1 could promote resistance to chemotherapy, and tumor and host CMTM6 knockout could promoted antitumor immune responses during chemotherapy. Moreover, we developed and evaluated the antitumor effects of CMTM6&PD-L1-targeting adeno-associated virus (AAV), which effectively mobilized antitumor immunity and could be combined with chemotherapy. Our findings reveal that both tumor- and host-derived CMTM6 and PD-L1 are regulatory molecules of chemotherapy resistance and can serve as therapeutic targets for combination therapy with chemotherapy.</p> 2026-09-14T11:46:57Z Dataset Dataset 10.3389/fimmu.2026.1886034.s002 https://figshare.com/articles/dataset/Supplementary_file_1_CMTM6_PD-L1-targeted_AAV_promotes_anti-tumor_immune_responses_and_chemotherapy_responsiveness_xls/33734242 CC BY 4.0